#PROUD

The controversial head of the AIDS Healthcare Foundation has taken his PrEP-skepticism campaign to the prestigious medical journal AIDS.

A push to diagnose and rapidly treat HIV and other STIs as well as use of Truvada as PrEP are likely driving the trend.

Following a recent finding of a major drop in HIV diagnoses at the 56 Dean St. clinic, the decline in gonorrhea diagnoses is encouraging.

An analysis of the “on-demand” PrEP study found no new HIV infections among those reporting good adherence and relatively infrequent sex.

In a British study, men on PrEP also reported many psychosocial benefits to using Truvada for prevention.

The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.

What does the future hold for new pre-exposure prophylaxis (PrEP) against HIV, including long-acting injectables and less toxic drugs?

The PROUD study, which found that PREP reduced HIV risk by 86 percent in English high-risk gay and bi men, has been published in the Lancet.

AIDS Healthcare Foundation published an ad criticizing pre-exposure prophylaxis (PrEP) in various gay publications around the country.

Canadian research suggests rolling out Truvada as PrEP to prevent HIV would save money even if cost to treat the virus drops in the future.

New research underscores the great potential of Truvada as pre-exposure prophylaxis for preventing HIV among gay and bisexual men.

A group of British gay and bi men given Truvada as PrEP had an overall 86 percent lower risk of HIV as a consequence.

A study of intermittent dosing of Truvada as PrEP among gay and bi men has been stopped due to the intervention’s high efficacy in...

Interim results of an English study of PrEP among gay and bi men and transgender women have shown high efficacy in preventing HIV.

Truvada as pre-exposure prophylaxis (PrEP) to prevent HIV has been slow to catch on, but the rate of new prescriptions appears to be...